Doctors are diagnosing more patients as US market normalizes, says Lundbeck CEO

The Covid-19 pandemic has been tough on several of the drugs sold by Lundbeck but the clouds seem to be lifting and recovery might be on the horizon, making Lundbeck ramp up marketing efforts of migraine drug Vyepti.

Photo: Gregers Tycho/ERH

Lundbeck's newest drugs have been received well, not least on the important US market, on which sales growth of key products appear to have forward momentum.

One of the primary causes is that American doctors have started seeing more patients, following a period of being heavily impacted by Covid-19, which kept patients out of clinics.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs